Laxmi Dental's 5 Lakh ESOP Shares Get Conditional BSE Approval

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorRiya Kapoor|Published at:
Laxmi Dental's 5 Lakh ESOP Shares Get Conditional BSE Approval
Overview

Laxmi Dental has received in-principle approval from BSE Limited to list 5 Lakh equity shares issued under its 2024 Employee Stock Option Scheme. This step is intended to reward employees and align their interests with the company's growth. The approval comes with conditions, requiring strict adherence to BSE guidelines and regulatory compliance.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Laxmi Dental Secures Conditional BSE Approval for ESOP Share Listing

Laxmi Dental Limited will list 5 Lakh equity shares, each with a face value of Rs. 2.

BSE Approval Granted

BSE Limited has given its initial approval for Laxmi Dental Limited to list 5 Lakh equity shares under its Employee Stock Option Scheme 2024. This approval is conditional on Laxmi Dental meeting all exchange requirements, including ensuring full statutory and regulatory compliance and providing accurate, non-misleading information.

Boosting Employee Alignment

The ESOP scheme aims to reward employees, attract and retain talent, and build a sense of ownership. By listing these shares, Laxmi Dental seeks to align employee interests more closely with shareholder goals, potentially boosting motivation and improving performance and retention.

Company Background and Recent Developments

Laxmi Dental is a prominent integrated dental products company offering laboratory services, aligners, and paediatric dental products with global exports. The company completed its IPO in January 2025. In a related development, Mr. Rajesh Khakhar, a Promoter and Whole-time Director, was discharged from a CBI case on March 20, 2025. The company's board also approved a merger with its subsidiary, Bizdent Devices Private Limited, in March 2026.

Impact on Employees and Shareholders

For employees granted options, this approval signifies that their future shares will be listed and tradable on the stock exchange, once vesting and exercise conditions are met. Existing shareholders may see a slight dilution of their stake when options are exercised. The process operates under the ESOP 2024 framework, approved by shareholders on August 16, 2024.

Key Compliance Hurdles

The main risk stems from the conditional nature of the BSE approval. Laxmi Dental must meticulously follow all specified conditions and regulations from authorities like SEBI and MCA. Failure to comply or any misrepresentation could result in the approval being withdrawn. Strict adherence to SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, is crucial.

Market Context

While direct comparisons for ESOP listing approvals are uncommon, Laxmi Dental operates within the dental products sector. Companies like India's Prevest Denpro Ltd focus on dental materials, while global firms such as Straumann Holding AG represent the broader dental technology market. Laxmi Dental's integrated approach, from manufacturing to distribution, sets it apart.

Key ESOP Metrics

Under the Laxmi Dental ESOP 2024 scheme, up to 500,000 options can be granted. Each equity share has a face value of Rs. 2.

Looking Ahead

Investors will be watching Laxmi Dental's compliance with all BSE conditions for the share listing. Key next steps include the formal allotment and credit of shares to employee accounts. The company must also notify the exchange as required by SEBI. Final trading permission from BSE will mark the completion of this process.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.